Acute ingestion of neuromuscular enhancement supplements do not improve power output, work capacity, and cognition
Related Experiment Video
Updated: Mar 7, 2026

A Murine Model of Muscle Training by Neuromuscular Electrical Stimulation
Published on: May 9, 2012
Jennifer A Bunn1, Andrew Crossley2, Morgan D Timiney3
1Department of Physical Therapy, Campbell University, Buies Creek, NC, USA - bunnj@campbell.edu.
Background:
Improving motor unit recruitment and function is trainable and positively affects performance. Evidence suggests that supplementation of choline, uridine, and docosahexaenoic acid (DHA) may also enhance neuromuscular function. The purpose of this study was to assess the influence of acute ingestion of these supplements on anaerobic exercise performance and cognition.
Methods:
Twenty college-aged trained males (21.2±1.4 years, 181.2±6.1 cm, 94.4±20.5 kg, and 15.9±6.6% body fat) received the supplements (SUPP: 500 mg alpha glycerophosphocholine [AGPC], 250 mg uridine-5'-monophosphate, and 1500 mg DHA) or a placebo (PLA) in a randomized cross-over study design. All participants completed one familiarization and two experimental testing sessions, consisting of a warm up, vertical jump assessment, 61-kg bench press rep max, and completion of the ImPACT neural cognition test. In the two testing sessions, participants received, in random order, either the SUPP or a PLA, 90 minutes before testing.
Results:
There was no significant difference between SUPP and PLA on exercise performance or neural cognition (P>0.05).
Conclusions:
The results of this study indicated no benefit from acute ingestion of a DHA, uridine, and choline supplement versus a placebo on anaerobic performance or cognition. It is likely that acute ingestion of these supplements did not provide the necessary elements to increase acetylcholine concentration or number of dendritic spines, rather ingestion for a longer time period and subsequent days may provide a benefit.
More Related Videos
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Neuromuscular Junction And Blockade
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

